Patritumab deruxtecan治疗非小细胞肺癌活动性脑转移的II期研究
TUXEDO-3是一项多中心单臂II期试验,评估HER3-DXd在晚期非小细胞肺癌活动性脑转移患者中的疗效与安全性。治疗相关不良事件发生率80%,无治疗相关死亡。
要点
- HER3-DXd在活动性脑转移NSCLC中颅内缓解率30%,达到预设阈值。
- 常见治疗相关不良事件为恶心、腹泻和乏力,3-4级以中性粒细胞减少为主。
- 未发现新的安全信号,无治疗相关死亡。
核心结论
- HER3-DXd在晚期NSCLC活动性脑转移患者中显示出有前景的临床活性,可能成为新的治疗选择。
研究设计与样本
- TUXEDO-3为多队列、多中心、开放标签、单臂II期试验,本队列纳入20例晚期NSCLC伴新诊断或局部治疗后进展的脑转移成人患者。
主要发现
- 6例缓解者均为非鳞状NSCLC,其中2例(33%)为未经治疗脑转移,4例(67%)为局部治疗后进展脑转移;1例(17%)携带KRAS G12C驱动突变。
- 治疗相关不良事件发生于16例(80%)患者,最常见为恶心(7例,35%)、腹泻和乏力(各6例,30%)。
- 3-4级不良事件最常见为中性粒细胞减少(3例,15%)和发热性中性粒细胞减少(2例,10%)。
关键数值与推荐
- 主要终点阈值:至少15%的患者达到颅内缓解(依据RANO-BM标准)。
临床怎么用
- HER3-DXd可能为晚期NSCLC活动性脑转移患者提供一种新的全身治疗选择,尤其对非鳞状NSCLC。
- 治疗期间需监测恶心、腹泻、乏力及中性粒细胞减少等不良事件。
局限性
- 种族数据不完整,4例患者未报告种族。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a novel antibody-drug conjugate targeting HER3, which is overexpressed in CNS metastases of advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the activity and safety of HER3-DXd in patients with advanced NSCLC and newly diagnosed brain metastases or brain metastases progressing after local therapy. METHODS: TUXEDO-3 is a multicohort, multicentre, open-label, single-arm phase 2 trial. In this cohort (2 of 3), we enrolled adults (aged ≥18 years) with histologically documented squamous or non-squamous NSCLC, radiologically documented metastatic disease, newly diagnosed brain metastases or progressing brain metastases after local treatment, at least one brain lesion, no need for immediate local therapy, and an Eastern Cooperative Oncology Group performance status of 0-2. Patients received HER3-DXd 5·6 mg/kg intravenously once every 3 weeks. The threshold to meet the primary endpoint was at least 15% of patients having an intracranial response according to Response Assessment in Neuro-Oncology Brain Metastases criteria. Activity and safety analyses were done in the full analysis set, which included all participants who received at least one dose of HER3-DXd. This trial (ClinicalTrials.govNCT05865990 and European Union Clinical Trials Register 2023-503251-10-00) is ongoing but no longer enrolling patients. FINDINGS: Between Dec 27, 2023, and Sept 6, 2024, 20 patients were recruited; ten (50%) were female and ten (50%) were male. 16 (80%) of 20 patients were White; race was not reported in the remaining four patients. 13 (65%) of the 20 patients had brain metastases progressing after local therapy and seven (35%) had untreated brain metastases; five (25%) had activating driver mutations. Median follow-up was 5·3 months (IQR 2·0-8·5). The primary endpoint was met, with six (30%) of 20 patients having intracranial responses (objective response rate 30·0%, 95% CI 11·9-54·3). The six responders had non-squamous advanced NSCLC (two [33%] with untreated brain metastases and four [67%] with progressing brain metastases), of whom one (17%) had an activating driver mutation (KRAS G12C). Treatment-related adverse events occurred in 16 (80%) patients, the most common of which were nausea (seven [35%] patients), and diarrhoea and asthenia (each six [30%] patients). The most common grade 3 and 4 adverse events were neutropenia in three (15%) patients and febrile neutropenia in two (10%). There were no treatment-related deaths, and no new safety signals were identified. INTERPRETATION: HER3-DXd showed promising clinical activity in patients with advanced NSCLC and active brain metastases, and could represent a novel treatment option in this setting. FUNDING: Daiichi-Sankyo and Merck Sharp & Dohme.
引用
- Fuereder T, Garde-Noguera J, García-Mosquera JJ, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025. PMID: 41167214. doi:10.1016/S1470-2045(25)00465-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。